Managing sleep issues in Parkinson's disease: an up-to-date review

被引:0
|
作者
Suzuki, Keisuke [1 ]
Fujita, Hiroaki [1 ]
Kobayashi, Saro [1 ]
机构
[1] Dokkyo Med Univ, Dept Neurol, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan
关键词
Parkinson's disease; insomnia; restless legs syndrome; rapid eye movement sleep behavior disorder; excessive daytime sleepiness; obstructive sleep apnea; circadian dysfunction; RESTLESS LEGS SYNDROME; EXCESSIVE DAYTIME SLEEPINESS; DISORDER SCREENING QUESTIONNAIRE; SYNDROME/WILLIS-EKBOM DISEASE; BEHAVIOR DISORDER; MOTOR RESTLESSNESS; NONMOTOR SYMPTOMS; DOUBLE-BLIND; OPEN-LABEL; APNEA;
D O I
10.1080/14737175.2025.2450789
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IntroductionIn Parkinson's disease (PD), sleep-wake problems are disease-related symptoms that occur throughout the day and have a negative impact on patients' quality of life to an extent that is equal to or greater than that of typical motor symptoms.Areas coveredInsomnia due to fragmented sleep and excessive daytime sleepiness (EDS) worsen as PD progresses. Nighttime wearing-off and early morning-off should be considered first when fragmented sleep is reported in PD patients. If the main complaint of patients with insomnia is difficulty falling asleep, restless legs syndrome should be differentiated first. Obstructive sleep apnea causes sleep quality deterioration and fragmented sleep. For rapid eye movement sleep behavior disorder (RBD), preventative measures against sleep-related trauma are necessary. RBD has also attracted attention as a PD precursor state and as a disease progression marker that is associated with specific PD clinical subtypes. In PD patients, the sleep-wake phase may advance/delay or become irregular due to circadian dysfunction.Expert opinionImportantly, sleep-wake problems are core symptoms related to the pathogenesis and progression of PD, and addressing a wide range of these symptoms will improve patients' quality of life.
引用
收藏
页码:211 / 226
页数:16
相关论文
共 50 条
  • [41] Management of hypodermitis or lipodermatosclerosis: an up-to-date review
    Reina-Gutierrez, Lourdes
    Sanjuanbenito-Reina, Alfonso
    PHLEBOLYMPHOLOGY, 2023, 30 (01) : 6 - 25
  • [42] Penile reconstruction: An up-to-date review of the literature
    Ottaiano, Nicholas
    Pincus, Joshua
    Tannenbaum, Jacob
    Dawood, Omar
    Raheem, Omer
    ARAB JOURNAL OF UROLOGY, 2021, 19 (03) : 353 - 362
  • [43] Antimicrobial polymeric paints: An up-to-date review
    Gupta, Sonali
    Puttaiahgowda, Yashoda Malgar
    Nagaraja, Akshatha
    Jalageri, Manohara Dhulappa
    POLYMERS FOR ADVANCED TECHNOLOGIES, 2021, 32 (12) : 4642 - 4662
  • [44] Neurotoxicity Induced by Mephedrone: An up-to-date Review
    Pantano, Flaminia
    Tittarelli, Roberta
    Mannocchi, Giulio
    Pacifici, Roberta
    di Luca, Alessandro
    Busardo, Francesco Paolo
    Marinelli, Enrico
    CURRENT NEUROPHARMACOLOGY, 2017, 15 (05) : 738 - 749
  • [45] Photodynamic Therapy-An Up-to-Date Review
    Niculescu, Adelina-Gabriela
    Grumezescu, Alexandru Mihai
    APPLIED SCIENCES-BASEL, 2021, 11 (08):
  • [46] UP-TO-DATE CHEMOTHERAPY AGAINST MONEGENEA - A REVIEW
    SCHMAHL, G
    BULLETIN FRANCAIS DE LA PECHE ET DE LA PISCICULTURE, 1993, (328): : 74 - 81
  • [47] Endogenous Morphine: Up-to-Date Review 2011
    Stefano, G. B.
    Ptacek, R.
    Kuzelova, H.
    Kream, R. M.
    FOLIA BIOLOGICA, 2012, 58 (02) : 49 - 56
  • [48] The modulation of coagulation by aptamers: an up-to-date review
    Hu, Piao-Ping
    Zhang, Kun-He
    BLOOD COAGULATION & FIBRINOLYSIS, 2015, 26 (01) : 1 - 6
  • [49] Pathogenesis of IgA Vasculitis: An Up-To-Date Review
    Song, Yan
    Huang, Xiaohan
    Yu, Guizhen
    Qiao, Jianjun
    Cheng, Jun
    Wu, Jianyong
    Chen, Jianghua
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [50] Mazabraud's Syndrome: A Case Report and Up-To-Date Literature Review
    Vescini, Fabio
    Falchetti, Alberto
    Tonelli, Veronica
    Carpentieri, Maria
    Cipri, Claudia
    Cosso, Roberta
    Kara, Elda
    Triggiani, Vincenzo
    Grimaldi, Franco
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2019, 19 (06) : 885 - 893